Influences of bone and mineral metabolism in epilepsy

Bibliography

• Hauser WA. Incidence and prevalence. In: Engel J, Pedley TA, editors, Epilepsy: a comprehensive textbook. Lippincott-Raven, Philadelphia; 1997. p. 47-57
   Google Scholar
• Linde J, Molholm Hansen J, Siersbaek-Nielsen K, Fuglsang-Fredriksen V. Bone density in patients receiving long-term anticonvulsant therapy. Acta Neurol Scand 1971;47(5):650-1
   PubMed Web of Science ®Google Scholar
• Nilsson OS, Lindholm TS, Elmestedt E, Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orthop Trauma Surg 1986;105(3):146-9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Tigaran S, Rejnmark L, Fracture risk is increased in epilepsy. Acta Neurol Scand 1999;99(5):269-75
   PubMed Web of Science ®Google Scholar
• Andress DL, Ozuna J, Tirschwell D, Antiepileptic drug induced bone loss in young male patients who have seizures. Arch Neurol 2002;59(5):781-90
   PubMed Web of Science ®Google Scholar
• Souverein PC, Webb DJ, Petri H, Incidence of fractures among epilepsy patients: a population based retrospective cohort study in the general practice research database. Epilepsia 2005;46(2):304-10
   PubMed Web of Science ®Google Scholar
• Hahn TJ. Steroid and drug-induced osteopenia. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 2nd edition. Raven Press, New York; 1993. p. 250-8
   Google Scholar
• Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med 1986;314(26):1676-86
   PubMed Web of Science ®Google Scholar
• Annegers JF, Melton III LJ, Sun CA, Hauser WA. Risk of age related fractures in patients with unprovoked seizures. Epilepsia 1989;30(3):348-55
   PubMed Web of Science ®Google Scholar
• Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55(3):273-86
   PubMed Web of Science ®Google Scholar
• Schettler AE, Gustafson EM. Osteoporosis prevention starts in adolescence. J Am Acad Nurse Pract 2004;16(7):274-82
   PubMedGoogle Scholar
• Intake of dietary calcium to reduce the incidence of osteoporosis. Council on Scientific Affairs, American Medical Association. Arch Family Med 1997;6(5):495-99
   PubMedGoogle Scholar
• Fitzpatrick LA. Bone metabolism-bone loss and injury in the female athlete. In: Swedan N, editor, Women's sport medicine and rehabilitation. Gaithersburg, MD: Aspen; 2001. p. 259-83
   Google Scholar
• Ducy P, Desbois C, Boyce B, Increased bone formation in osteocalcin-deficient mice. Nature 1996;382(6590):448-52
   PubMed Web of Science ®Google Scholar
• Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care 2001;4(6):483-7
   PubMed Web of Science ®Google Scholar
• Munroe PB, Olgenturk RO, Fryns JP, Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 1999;21(1):142-4
   PubMed Web of Science ®Google Scholar
• Adamek G, Felix R, Guenther HL, Fleisch H. Fatty acid oxidation in bone tissue and bone cells in culture. Biochem J 1987;248(1):129-37
   PubMed Web of Science ®Google Scholar
• Broadus AE. Mineral balance and homeostasis. In: Favus MJ, editor, Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th edition. Lippincott Williams & Wilkins, Philadelphia; 1999. p. 74-80
   Google Scholar
• Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev 1992;13(1):66-80
   PubMed Web of Science ®Google Scholar
• McSheehy PM, Chambers TJ. Osteoblast-like cells in the presence of parathyroid hormone release a soluble factor that stimulates osteoclastic bone resorption. Endocrinology 1986;119(4):1654-9
   PubMed Web of Science ®Google Scholar
• Cornish J, Callon KE, Bava U, Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 2001;29(2):162-8
   PubMed Web of Science ®Google Scholar
• Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987;8(4):426-8
   PubMed Web of Science ®Google Scholar
• Kassem M, Blum W, Ristelli J, Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif Tissue Int 1993;52(3):222-6
   PubMed Web of Science ®Google Scholar
• Lewinson D, Shenzer P, Hochberg Z. Growth hormone involvement in the regulation of tartrate-resistant acid phosphatase-positive cells that are active in cartilage and bone resorption. Calcif Tissue Int 1993;52(3):216-21
   PubMed Web of Science ®Google Scholar
• Saggese G, Federico G, Cinquanta L. In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast-like cells. Acta Paediatr Suppl 1993;82(S391):54-9
   PubMedGoogle Scholar
• Mochizuki H, Hakeda Y, Wakatsuki N, Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 1992;131(3):1075-80
   PubMed Web of Science ®Google Scholar
• Tomkinson A, Gevers EF, Wit JM, The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998;13(8):1243-50
   PubMed Web of Science ®Google Scholar
• Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359(9320):1841-50
   PubMed Web of Science ®Google Scholar
• DeLuca H. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB J 1988;2(3):224-36
   PubMed Web of Science ®Google Scholar
• Bland R, Walker EA, Hughes SV, Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 1999;140(5):2027-34
   PubMed Web of Science ®Google Scholar
• Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999;(2 Pt 2):F157-75
   Google Scholar
• Horowitz MC, Xi Y, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12(1):9-18
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139(3):1329-37
   PubMed Web of Science ®Google Scholar
• Stanley ER, Berg KL, Einstein DB, Biology and action of colony – stimulating factor-1. Mol Reprod Dev 1997;46(1):4-10
   PubMed Web of Science ®Google Scholar
• Bouillon R, Reynaert J, Claes JH, The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975;41(6):1130-5
   PubMed Web of Science ®Google Scholar
• Hahn TJ, Scharp CR, Halstead LR, Parathyroid hormone status and renal responsiveness in familial hypophosphatemic rickets. J Clin Endocrinol Metab 1975;41(5):926-37
   PubMed Web of Science ®Google Scholar
• Bowe AE, Finnegan R, Jan de Beur SM, FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284(4):977-81
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2004;90(3):1519-24
   PubMed Web of Science ®Google Scholar
• Borum PR. Regulation of carnitine concentration in plasma. In: Frenkel RA, McGarry JD, editors, Carnitine biosynthesis, metabolism and functions. Academic Press, New York; 1980. p. 115-26
   Google Scholar
• Colucci S, Mori G, Vaira S, L-Carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 2005;76(6):458-65
   PubMed Web of Science ®Google Scholar
• Patano N, Mancini L, Settanni MP, L-Carnitine fumarate and isovaleryl-L-Carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimentally induced osteoporosis in pregnant mice. Calcif Tissue Int 2008;82(3):221-8
   PubMed Web of Science ®Google Scholar
• Jones G, Cooley HM. Symptomatic fracture incidence in those under 50 years of age in southern Tasmania. J Paediatr Child Health 2002;38(3):278-83
   PubMed Web of Science ®Google Scholar
• Henderson RC, Lark RK, Gurka MJ, Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002;110(1 Pt 1):e5
   PubMed Web of Science ®Google Scholar
• Lindsay R, Pack S, Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int 2005;16(3):306-12
   PubMed Web of Science ®Google Scholar
• Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994;16(5):382-85
   PubMed Web of Science ®Google Scholar
• Verrotti A, Greco R, Latini G, Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43(12):1488-92
   PubMed Web of Science ®Google Scholar
• Sato Y, Kondo I, Ishida S, Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001;57(3):445-9
   PubMed Web of Science ®Google Scholar
• Boluk A, Guzelipek M, Savli H, The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004;50(1):93-7
   PubMed Web of Science ®Google Scholar
• Valimaki MJ, Tiihonen M, Laitinen K, Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9(5):631-7
   PubMed Web of Science ®Google Scholar
• Coppola G, Fortunato D, Auricchio G, Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009;50(9):2140-6
   PubMed Web of Science ®Google Scholar
• Nissen-Meyer LS, Svalheim S, Tauboll E, Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007;48(10):1850-60
   PubMed Web of Science ®Google Scholar
• Gou CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001;42(9):1141-7
   PubMed Web of Science ®Google Scholar
• Nissen-Meyer LS, Svalheim S, Tauboll E, Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007;48(10):1850-60
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Mclellan AR, Harrison JH, Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8(6):339-42
   PubMed Web of Science ®Google Scholar
• Sheth R, Hermann B. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 2007;37(4):250-4
   PubMed Web of Science ®Google Scholar
• Rauchenzauner M, Griesmacher A, Tatarczyk T, Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children. Dev Med Child Neurol 2010;52(3):283-8
   PubMed Web of Science ®Google Scholar
• Pack AM, Morrell MJ, Marcus R, Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57(2):252-7
   PubMed Web of Science ®Google Scholar
• Pack AM, Morrell MJ, Randall A, Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008;70(18):1586-93
   PubMed Web of Science ®Google Scholar
• von Borstel Smith M, Crofoot K, Rodriguez-Proteau R, Filtz TM. Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro 2007;21(5):855-62
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Bryce GF, Sappington LJ, Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984;58(6):1003-9
   PubMed Web of Science ®Google Scholar
• Bogliun G, Beghi E, Crespi V, Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986;74(4):284-8
   PubMed Web of Science ®Google Scholar
• Mosekilde L, Melsen F. Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions. Metab Acta Pathol Microbiol Scand A 1980;88(2):83-8
   PubMedGoogle Scholar
• Gough H, Bissesar A, Goggin T, Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy. Ir J Med Sci 1986;155(6):181-9
   PubMed Web of Science ®Google Scholar
• Parfitt AM. The physiologic and pathogenetic significance of bone histomorphometric data. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism. Raven Press, New York; 2002. p. 469-88
   Google Scholar
• Eriksen EF, Charles P, Melsen F, Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993;8(2):127-32
   PubMed Web of Science ®Google Scholar
• Telci A, Cakatay U, Kurt BB, Changes in bone turnover and deoxypyridinoline levels in epileptic patients. Clin Chem Lab Med 2000;38(1):47-50
   PubMed Web of Science ®Google Scholar
• Zhou C, Assem M, Tay JC, Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and druginduced osteomalacia. J Clin Invest 2006;116(6):1703-12
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Robert A, Nguyen M, Possible involvement or pregnane X receptor-enhanced CYP 24 expression in drug-induced osteomalacia. J Clin Invest 2005;115(1):177-86
   PubMed Web of Science ®Google Scholar
• Mikati MA, Dib L, Yamout B, Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 2006;67(11):2005-14
   PubMed Web of Science ®Google Scholar
• Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004;5(Suppl 2):S36-40
   PubMed Web of Science ®Google Scholar
• Lande MB, Kim MS, Bartlett C, Reversible Fanconi syndrome associated with valproate therapy. J Pediatr 1993;123(2):320-22
   PubMed Web of Science ®Google Scholar
• Hahn TJ, Scharp CR, Richardson CA, Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J Clin Invest 1978;62(2):406-14
   PubMed Web of Science ®Google Scholar
• Lentz SR, Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med 2004;71(9):729-34
   PubMed Web of Science ®Google Scholar
• McClean RR, Jacques PF, Selhub J, Homocysteine as a predictive factor for hip fractures in older persons. N Engl J Med 2004;350(20):2042-9
   PubMed Web of Science ®Google Scholar
• Goldbahar J, Hamidi A, Aminzadeh AA, Omrani GR. Association of plasma folate, plasma homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004;7(3):60-5
   Google Scholar
• Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005;118(11):1250-5
   PubMed Web of Science ®Google Scholar
• Olszynski WP, Davison KS, Adachi JD, Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004;26(1):15-28
   PubMed Web of Science ®Google Scholar
• Pack A. Effects of treatment on endocrine function in patients with epilepsy. Curr Treat Options Neurol 2005;7(4):273-80
   PubMedGoogle Scholar
• Verrotti A, Greco R, Morgese G, Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res 1999;29(1):36-40
   PubMedGoogle Scholar
• Fung ELW, Tang NLS, Ho CS, Carnitine level in Chinese epileptic patients taking sodium valproate. Pediatr Neurol 2003;28(1):24-7
   PubMed Web of Science ®Google Scholar
• Hirose S, Mitsudome A, Yasumoto S, Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;101(5):E9
   PubMed Web of Science ®Google Scholar
• Hamed SA, Mahmoud MA. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res 2009;86(1):32-41
   PubMed Web of Science ®Google Scholar
• Farkas V, Bock I, Cseko J, Sandor A. Inhibition of carnitine biosynthesis by valproic acid in rats – the biochemical mechanism of inhibition. Biochem Pharmacol 1996;52(9):1429-33
   PubMed Web of Science ®Google Scholar
• Haas R, Stumpf DA, Parks JK, Eguren L. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981;31(11):1473-76
   PubMed Web of Science ®Google Scholar
• Rogiers V, Bandenberghe Y, Vecuysse A. Inhibition of gluconeogenesis by sodium valproate and its metabolite in isolated rate hepatocytes. Xenobiotica 1985;15(8-9):759-65
   PubMed Web of Science ®Google Scholar
• Laub MC. Hyperammonemia in valproate therapy in children and adolescents. Nervenarzt 1986;57(5):314-18
   PubMed Web of Science ®Google Scholar
• Warter JM, Brandt C, Marescaux C, The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 1983;33(9):1136-40
   PubMed Web of Science ®Google Scholar
• Chalmers RA, Roe CR, Stacey TE, Hoppel CL. Urinary excretion of L-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr Res 1984;18(12):1325-8
   PubMed Web of Science ®Google Scholar
• Kruse K, Kracht U. Inhibition of calcitonin secretion/synthesis by anticonvulsant drugs. Acta Endocrinol 1981;96(3):38-9
   Google Scholar
• Pento JT, Glick SM, Kagan A. Diphenylhydantoin inhibition of calcitonin secretion in the pig. Endocrinology 1973;92(1):330-3
   PubMed Web of Science ®Google Scholar
• Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002;70(13):1533-42
   PubMed Web of Science ®Google Scholar
• Scott AK, Haynes BP, Schinkel KD, Hepatic enzyme induction and vitamin K1 elimination in man. Eur J Clin Pharmacol 1987;33(1):93-5
   PubMed Web of Science ®Google Scholar
• Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 1990;11(5):309-12
   PubMed Web of Science ®Google Scholar
• Nakade O, Baylink DJ, Lau KH. Phenytoin at micromolar concentrations is an osteogenic agent for human-mandiblederived bone cells in vitro. J Dent Res 1995;74(1):331-7
   PubMed Web of Science ®Google Scholar
• Collins N, Maher J, Cole M, Aprospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991;78(286):113-22
   PubMedGoogle Scholar
• Auszmann JM, Vernillo AT, Fine SA, Rifkin BR. The effect of phenytoin on parathyroid hormone stimulated cAMP activity in cultured murine osteoblasts. Life Sci 1990;46(5):351-7
   PubMed Web of Science ®Google Scholar
• Peterson P, Gray P, Tolman KG. Calcium balance in drug-induced osteomalacia: response to vitamin D. Clin Pharmacol Ther 1976;19(1):63-7
   PubMed Web of Science ®Google Scholar
• Rattya J, Turkka J, Pakarinen AJ, Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001;56(1):31-6
   PubMed Web of Science ®Google Scholar
• Roste LS, Tauboll E, Morkrid L, Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. Eur J Neurol 2005;12(2):118-24
   PubMed Web of Science ®Google Scholar
• Hamed SA, Mohamed KA, EL-taher AM, The sexual and reproductive health in men with generalized epilepsy: a multidisciplinary evaluation. Int J Impot Res 2006;18(3):287-95
   PubMed Web of Science ®Google Scholar
• Lofgren E, Tapanainen JS, Koivunen R, Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia 2006;47(9):1441-6
   PubMed Web of Science ®Google Scholar
• Perucca E, Hedges A, Makki KA, A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 2004;58(7):S854-63
   PubMed Web of Science ®Google Scholar
• Murialdo G, Galimberti CA, Gianelli MV, Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21(1):52-8
   PubMed Web of Science ®Google Scholar
• Isojarvi JIT, Pakarinen AJ, Ylipalosaari PJ, Serum hormones in male patients with epilepsy patients receiving anticonvulsant medication. Arch Neurol 1990;47(6):670-6
   PubMed Web of Science ®Google Scholar
• Isojarvi JI, Pakarinen AJ, Rautio A, Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995;47:461-4
   PubMed Web of Science ®Google Scholar
• Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359(9320):1841-50
   PubMed Web of Science ®Google Scholar
• Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58(9):1369-74
   PubMed Web of Science ®Google Scholar
• Kim KK, Horan ML, Gendler P. Osteoporosis knowledge tests, osteoporosis health belief scale, and osteoporosis self-efficacy scale. Grand Valley State University, Allendale, MI; 1991
   Google Scholar
• Available from: http://www.shef.ac.uk/FRAX/
   Google Scholar
• Watts NB, Lewiecki EM, Miller PD, Baim S. National osteoporosis foundation 2008 Clinician's guide to prevention and treatment of osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008;11(4):473-7
   PubMed Web of Science ®Google Scholar
• Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Bone mineral metabolism in adults with beta-thalassemia major and intermedia. Br J Haematol 2000;111(3):902-7
   PubMed Web of Science ®Google Scholar
• Eren E, Yilmaz N. Biochemical markers of bone turnover and bone mineral density in patients with beta-thalassemia major. Int J Clin Pract 2005;59(1):46-51
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18(8):1033-46
   PubMed Web of Science ®Google Scholar
• Kanis JA. World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. University of Sheffield; 2008
   Google Scholar
• Gordon CM, Baim S, Bianchi ML, Special report on the 2007 Pediatric Position Development Conference of the International Society for Clinical Densitometry. South Med J. 2008;101(7):740-3
   PubMed Web of Science ®Google Scholar
• Leonard MB, Propert KJ, Zemel BS, Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia. J Pediatr 1999;135(2 Pt 1):182-8
   PubMed Web of Science ®Google Scholar
• Chan MF, Kwong WS, Zang YL, Wan PY. Evaluation of an osteoporosis prevention education programme for young adults. Journal of Advanced Nursing, 2007;57(3):270-85
   PubMed Web of Science ®Google Scholar
• Epilepsy Action. (2003). Anti-epileptic drugs and the risk of osteoporosis and osteomalacia: how much information do patients taking anti-epileptic drugs feel they receive about side effects of this medication? [Retrieved 1 June 2005]. Available from www.epilepsy.org.uk/research/reports/osteoporosis.html
   Google Scholar
• Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004;5(Suppl 2):S41-7
   PubMed Web of Science ®Google Scholar
• Greer FR, Krebs NF, Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006;117:578-85
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D. Available from: http://ods.od.nih.gov/factsheets/vitamind.asp
   Google Scholar
• Saintonge S, Bang H, Gerber JM. Implications of a new definition of vitamin D deficiency in a multiracial US adolescent population: the National health and nutrition examination survey III. Pediatrics 2009;123:797-803
   PubMed Web of Science ®Google Scholar
• Erbayat Altay E, Serdaroglu A, Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13(7):933-9
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Bagni B, Zini A, Relation of folates, vitamin B12 and homocysteine to vertebral bone mineral density change in postmenopausal women. A five-year longitudinal evaluation. Bone 2008;42(2):314-20
   PubMed Web of Science ®Google Scholar
• De Vivo DC, Bohan TP, Coulter DL, L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 1998;39(11):1216-25
   PubMed Web of Science ®Google Scholar
• Christiansen C, Rodbro P. Treatment of anticonvulsant osteomalacia with vitamin D. Calcif Tissue Res 1976;21(suppl):252-9
   PubMedGoogle Scholar
• Sherk HH, Cruz M, Stambaugh J. Vitamin D prophylaxis and the lowered incidenceof fractures in anticonvulsant rickets and osteomalacia. Clin Orthop 1977;129:251-7
   PubMed Web of Science ®Google Scholar
• Liakakos D, Papadopoulos Z, Vlachos P, Serum alkaline phosphatase and urinary hydroxyproline values in children receiving Phenobarbital with and without vitamin D. J Pediatr 1975;87(2):291-6
   PubMed Web of Science ®Google Scholar
• Fischer MH, Adkins WN Jr, Liebl BH, Bone status in nonambulant, epileptic, institutionalized youth. Clin Pediatr 1988;27(10):499-505
   PubMed Web of Science ®Google Scholar
• Collins N, Maher J, Cole M, A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug–induced osteomalacia. Q J Med 1991;78(286):113-22
   PubMedGoogle Scholar
• Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008;15(3):284-304
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas 2008;60(1):65-9
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16(1):87-116
   PubMed Web of Science ®Google Scholar
• Ebeling PR. Idiopathic or hypogonadal osteoporosis in men: current and future treatment options. Treat Endocrinol 2004;3(6):381-91
   PubMedGoogle Scholar
• Whyte MP, Wenkert D, Clements KL, Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349(5):457-63
   PubMed Web of Science ®Google Scholar